Skip to main content
SpringerLink
Log in

Individualize treatment for vernal keratoconjunctivitis based on clinical features and personal preferences

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Due to the lack of clarity regarding the pathogenesis of vernal keratoconjunctivitis, the treatment of this condition is challenging. The therapeutic regimen should be selected from among the many options (e.g. oral and/or topical mast-cell stabilizers, antihistamines, corticosteroids, and immunomodulators) based on the clinical features of the disease, personal preferences of the patient and clinical experience of the prescriber. Moderate-to-severe vernal keratoconjunctivitis may require topical corticosteroid treatment during the acute phase, followed by topical ciclosporin or tacrolimus for long-term management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kumar S. Vernal conjunctivitis: a major review. Acta Ophthalmol. 2009;87(2):133–47.

    Article  CAS  PubMed  Google Scholar 

  2. Esposito S, Fior G, Mori A, et al. An update on the therapeutic approach to vernal keratoconjunctivitis. Paediatr Drugs. 2016;18(5):347–55.

    Article  PubMed  Google Scholar 

  3. Bonini S, Sacchetti M, Mantelli F, et al. Clinical grading of vernal keratoconjunctivitis. Curr Opin Allergy Clin Immunol. 2007;7(5):436–41.

    Article  PubMed  Google Scholar 

  4. Bonini S, Bonini S, Lambiase A, et al. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmology. 2000;107(6):1157–63.

    Article  CAS  PubMed  Google Scholar 

  5. Pattnaik L, Acharya L. A comprehensive review on vernal keratoconjunctivitis with emphasis on proteomics. Life Sci. 2015;128:47–54.

    Article  CAS  PubMed  Google Scholar 

  6. Leonardi A, Borghesan F, Faggian D, et al. Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. Am J Ophthalmol. 2000;129(2):151–8.

    Article  CAS  PubMed  Google Scholar 

  7. Tabbara KF. Tear tryptase in vernal keratoconjunctivitis. Arch Ophthalmol. 2001;119(3):338–42.

    Article  CAS  PubMed  Google Scholar 

  8. Zicari AM, Zicari A, Nebbioso M, et al. High-mobility group box-1 (HMGB-1) and serum soluble receptor for advanced glycation end products (sRAGE) in children affected by vernal keratoconjunctivitis. Pediatr Allergy Immunol. 2014;25(1):57–63.

    Article  PubMed  Google Scholar 

  9. De Smedt S, Wildner G, Kestelyn P. Vernal keratoconjunctivitis: an update. Br J Ophthalmol. 2013;97(1):9–14.

    Article  PubMed  Google Scholar 

  10. Tuft SJ, Dart JK, Kemeny M. Limbal vernal keratoconjunctivitis: clinical considerations and immunoglobulin E expression compared with palpebral vernal. Eye (Lond). 1989;3(Pt 4):420–7.

    Article  PubMed  Google Scholar 

  11. Zicari AM, Nebbioso M, Lollobrigida V, et al. Vernal keratoconjunctivitis: atopy and autoimmunity. Eur Rev Med Pharmacol Sci. 2013;17(10):1419–23.

    CAS  PubMed  Google Scholar 

  12. Vichyanond P, Pacharn P, Pleyer U, et al. Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes. Pediatr Allergy Immunol. 2014;25(4):314–22.

    Article  PubMed  Google Scholar 

  13. Griffin RY, Sarici A, Unal L. Acquired ptosis secondary to vernal conjunctivitis in young adults. Ophthal Plast Reconstr Surg. 2006;22(6):438–40.

    Article  PubMed  Google Scholar 

  14. Le Q, Hong J, Zhu W, et al. In vivo laser scanning confocal microscopy of vernal keratoconjunctivitis. Clin Exp Ophthalmol. 2011;39(1):53–60.

    PubMed  Google Scholar 

  15. Church MK, McGill JI. Human ocular mast cells. Curr Opin Allergy Clin Immunol. 2002;2(5):419–22.

    Article  PubMed  Google Scholar 

  16. Kumar S, Gupta N, Vivian AJ. Modern approach to managing vernal keratoconjunctivitis. Curr Allergy Asthma Rep. 2010;10(3):155–62.

    Article  CAS  PubMed  Google Scholar 

  17. Weimer LK, Gamache DA, Yanni JM. Histamine-stimulated cytokine secretion from human conjunctival epithelial cells: inhibition by the histamine H1 antagonist emedastine. Int Arch Allergy Immunol. 1998;115(4):288–93.

    Article  CAS  PubMed  Google Scholar 

  18. Bielory L, Ghafoor S. Histamine receptors and the conjunctiva. Curr Opin Allergy Clin Immunol. 2005;5(5):437–40.

    Article  CAS  PubMed  Google Scholar 

  19. Bertelmann E, Pleyer U. Immunomodulatory therapy in ophthalmology: is there a place for topical application? Ophthalmologica. 2004;218(6):359–67.

    Article  CAS  PubMed  Google Scholar 

  20. Fukushima A. Roles of T-cells in the development of allergic conjunctival diseases. Cornea. 2007;26(9):S36–40.

    Article  PubMed  Google Scholar 

  21. Keklikci U, Dursun B, Cingu AK. Topical cyclosporine A 0.05% eyedrops in the treatment of vernal keratoconjunctivitis: randomized placebo-controlled trial. Adv. Clin Exp Med. 2014;23(3):455–61.

    Article  Google Scholar 

  22. Soparkar CN, Wilhelmus KR, Koch DD. Acute and chronic conjunctivitis due to over-the-counter ophthalmic decongestants. Arch Ophthalmol. 1997;115(1):34–8.

    Article  CAS  PubMed  Google Scholar 

  23. Leonardi A. Management of vernal keratoconjunctivitis. Ophthalmol Ther. 2013;2(2):73–88.

    Article  PubMed  PubMed Central  Google Scholar 

  24. McGill JI. A review of the use of olopatadine in allergic conjunctivitis. Int Ophthalmol. 2004;25(3):171–9.

    Article  PubMed  Google Scholar 

  25. Hida WT, Nogueira DC, Schaefer A, et al. Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis [in Portuguese]. Arq Bras Oftalmol. 2006;69(6):851–6.

    Article  PubMed  Google Scholar 

  26. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol. 2000;11(6):478–83.

    Article  CAS  PubMed  Google Scholar 

  27. McGhee CNJ, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002;25(1):33–55.

    Article  CAS  PubMed  Google Scholar 

  28. Sharma A, Gupta R, Ram J, et al. Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis. Indian J Ophthalmol. 1997;45(3):177–80.

    CAS  PubMed  Google Scholar 

  29. D’Angelo G, Lambiase A, Cortes M, et al. Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis. Graefe’s Arch Clin Exp Ophthalmol. 2003;241(3):192–5.

    Article  Google Scholar 

  30. Gupta S, Khurana AK, Ahluwalia BK, et al. Topical indomethacin for vernal keratoconjunctivitis. Acta Ophthalmol (Copenh). 1991;69(1):95–8.

    Article  CAS  PubMed  Google Scholar 

  31. Vichyanond P, Kosrirukvongs P. Use of cyclosporine A and tacrolimus in treatment of vernal keratoconjunctivitis. Curr Allergy Asthma Rep. 2013;13(3):308–14.

    Article  CAS  PubMed  Google Scholar 

  32. Labcharoenwongs P, Jirapongsananuruk O, Visitsunthorn N, et al. A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. Asian Pac J Allergy Immunol. 2012;30(3):177–84.

    CAS  PubMed  Google Scholar 

  33. Pucci N, Caputo R, di Grande L, et al. Tacrolimus vs. cyclosporine eyedrops in severe cyclosporine-resistant vernal keratoconjunctivitis: a randomized, comparative, double-blind, crossover study. Pediatr Allergy Immunol. 2015;26(3):256–61.

    Article  PubMed  Google Scholar 

  34. de Klerk TA, Sharma V, Arkwright PD, et al. Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab. J AAPOS. 2013;17(3):305–6.

    Article  PubMed  Google Scholar 

  35. Sohn J, Kim T-I, Yoon Y-H, et al. Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis. J Clin Invest. 2003;111(1):121–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Yanni JM, Sharif NA, Gamache DA, et al. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs. Acta Ophthalmol Scand Suppl. 1999;228:33–7.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Ethics declarations

    The article was adapted from Pediatric Drugs 2016; 18(5):347–55 [2] by salaried employees of Adis/Springer and was not supported by any external funding.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. Individualize treatment for vernal keratoconjunctivitis based on clinical features and personal preferences. Drugs Ther Perspect 33, 272–276 (2017). https://doi.org/10.1007/s40267-017-0405-y

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-017-0405-y

    Keywords

    Search

    Navigation